Kiora Pharmaceuticals: Navigating Retinal Diseases with KIO-301 and KIO-104
ByAinvest
Tuesday, Nov 4, 2025 5:53 am ET1min read
KPRX--
Kiora Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for retinal diseases. Its two drug candidates, KIO-301 and KIO-104, are under clinical development. KIO-301 aims to restore visual function in patients with retinitis pigmentosa by targeting surviving cells in the retina. A phase 2 trial, ABACUS-2, is underway to investigate the safety, tolerability, and efficacy of up to 3 doses of KIO-301 administered by IVT injection bilaterally every 6 weeks. KIO-104 is being developed for the treatment of diabetic macular edema and is currently in a phase 1 trial.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet